CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Explore scenarios where incorporating mutual funds into an index-based portfolio can improve diversification and adaptability.
24,945 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Pfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
A biotech stock nearly 300% pop grabbed the attention of major investors, culminating in a $68.7 million stake as a b...
A Tuesday uptick in Edgewise Therapeutics stock topped the market, driven by an upbeat price target from a major bank...
When a metropolitan bank director sells shares, it catches the eye of investors. This article explains insider filing...
Two major travel stocks have caught the eye of billionaire activist investors. This article breaks down what could ha...
Investors are debating whether monday.com stock going $128? is just a dream or a reachable milestone. This article br...
A senior executive at Ziff Davis sold a sizable block of shares. This article dives into what that move could mean fo...
The GTLB story has investors buzzing about whether a rebound is ahead. Even as revenue trends stay strong, the stock ...
US Treasuries are amplifying market selloffs, dragging Bitcoin lower as risk-off trades surge. Analysts say tradition...
A couple with $3.4 million plans to retire at 59 by drawing from a taxable portfolio for eight years, then tapping ta...
Yields on the 10-year Treasury push toward a key 4.75% level as investors weigh dividend-growth strategies against hi...